ArticleClinical interventions in aging2025
Diagnostic Value of 18F-FDG PET/CT Parameters Combined with Serum FOXM1 for Lymph Node Metastasis in Colorectal Cancer.
Article in Clinical interventions in aging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To evaluate the diagnostic value of maximum standardized uptake value (SUVmax), total lesion glycolysis (TLG), and metabolic tumor volume (MTV) in 18F-FDG PET/CT combined with serum forkhead box protein M1 (FOXM1) for detecting lymph node metastasis (LNM) in colorectal cancer (CRC). Methods: A retrospective study was conducted on 107 CRC patients who underwent 18F-FDG PET/CT and serum FOXM1 testing, with postoperative pathology as the reference standard. Patients were divided into LNM-positive (n=52) and LNM-negative (n=55) groups. PET/CT metabolic parameters (SUVmax, TLG, MTV) and serum FOXM1 levels were compared, correlations were analyzed by Spearman's test, and receiver operating characteristic (ROC) curves were plotted to assess diagnostic efficacy. Results: SUVmax was significantly higher in LNM-negative patients, whereas TLG, MTV, and serum FOXM1 were higher in LNM-positive patients (all P<0.05). Serum FOXM1 showed negative correlation with SUVmax (r=-0.356) and positive correlation with TLG and MTV (r=0.564, 0.549). The combined model of SUVmax, TLG, MTV, and FOXM1 yielded the highest diagnostic performance (AUC=0.971, sensitivity=92.2%, specificity=94.3%). Conclusion: SUVmax, TLG, MTV, and FOXM1 are interrelated and, when combined, provide superior diagnostic value for CRC LNM, though validation in larger, multicenter cohorts is needed.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.